Disseminated Kaposi sarcoma patients exhibit an expanded population of CD8+CD57+ T cells and an immunosenescence profile.

ABSTRACT:

Introduction

Kaposi's sarcoma herpesvirus (KSHV) remains the most common opportunistic malignancy that contributes to morbidity and mortality among persons living with HIV (PLWH) worldwide. The immune response in PLWH can exhibit signs of functional exhaustion, characterized by CD57 expression and mitochondrial dysfunction in T-cells. Valganciclovir (VGC), as an add-on therapy in patients with disseminated Kaposi Sarcoma/human immunodeficiency virus (DKS/HIV), modulates the activation of T-cell subsets; however, its effect on the T-cell immunosenescence profile is unclear.

Methods

This study evaluated the T-cell immunosenescence profile in DKS/HIV patients who received two treatment schedules: A group received antiretroviral therapy (cART) as conventional therapy (CT, n=10),

SUBMITTER: Flores-Gonzalez J 

PROVIDER: S-EPMC12592047 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature